Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose Escalation Study of Intravenously Administered NS-9 in Subjects With Liver Metastases From Various Primary Cancers

NCT00094003 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT00094003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00094003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose Escalation Study of Intravenously Administered NS-9 in Subjects With Liver Metastases From Various Primary Cancers
Lead sponsor
NS Pharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2002
Completion date
Not reported
Enrollment
20
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

liver neoplasms, local neoplasm recurrences, neoplasm metastasis